XML 121 R37.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenue by product | Revenues by product are summarized as follows:
| For the Years Ended December 31,
| 2019 |  | 2018 |  | 2017
(In millions) | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 3,306.5 |  |  | $ | 1,126.2 |  |  | $ | 4,432.7 |  |  | $ | 3,253.2 |  |  | $ | 1,020.9 |  |  | $ | 4,274.1 |  |  | $ | 3,294.0 |  |  | $ | 920.0 |  |  | $ | 4,214.0 |
Interferon* | 1,426.6 |  |  | 675.2 |  |  | 2,101.8 |  |  | 1,668.3 |  |  | 694.7 |  |  | 2,363.0 |  |  | 1,889.1 |  |  | 756.7 |  |  | 2,645.8 |
TYSABRI | 1,041.8 |  |  | 850.4 |  |  | 1,892.2 |  |  | 1,025.0 |  |  | 839.0 |  |  | 1,864.0 |  |  | 1,113.8 |  |  | 859.3 |  |  | 1,973.1 |
VUMERITY | 5.5 |  |  | — |  |  | 5.5 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
FAMPYRA | — |  |  | 97.1 |  |  | 97.1 |  |  | — |  |  | 92.7 |  |  | 92.7 |  |  | — |  |  | 91.6 |  |  | 91.6 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |  |  | — |  |  | 52.7 |  |  | 52.7 |
Subtotal: MS Product Revenues | 5,780.4 |  |  | 2,748.9 |  |  | 8,529.3 |  |  | 5,946.5 |  |  | 2,648.7 |  |  | 8,595.2 |  |  | 6,296.9 |  |  | 2,680.3 |  |  | 8,977.2 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 933.4 |  |  | 1,163.6 |  |  | 2,097.0 |  |  | 854.0 |  |  | 870.2 |  |  | 1,724.2 |  |  | 657.0 |  |  | 226.7 |  |  | 883.7 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 486.2 |  |  | 486.2 |  |  | — |  |  | 485.2 |  |  | 485.2 |  |  | — |  |  | 370.8 |  |  | 370.8 |
IMRALDI | — |  |  | 184.0 |  |  | 184.0 |  |  | — |  |  | 16.7 |  |  | 16.7 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 68.1 |  |  | 68.1 |  |  | — |  |  | 43.2 |  |  | 43.2 |  |  | — |  |  | 9.0 |  |  | 9.0 |
Subtotal: Biosimilar product revenues | — |  |  | 738.3 |  |  | 738.3 |  |  | — |  |  | 545.1 |  |  | 545.1 |  |  | — |  |  | 379.8 |  |  | 379.8 |
Other: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 15.2 |  |  | 15.2 |  |  | — |  |  | 22.3 |  |  | 22.3 |  |  | — |  |  | 39.6 |  |  | 39.6 |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 42.2 |  |  | 6.2 |  |  | 48.4 |
ALPROLIX | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 21.0 |  |  | 5.0 |  |  | 26.0 |
Subtotal: Hemophilia product revenues | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 63.2 |  |  | 11.2 |  |  | 74.4 |
Total product revenues | $ | 6,713.8 |  |  | $ | 4,666.0 |  |  | $ | 11,379.8 |  |  | $ | 6,800.5 |  |  | $ | 4,086.3 |  |  | $ | 10,886.8 |  |  | $ | 7,017.1 |  |  | $ | 3,337.6 |  |  | $ | 10,354.7 |
*Interferon includes AVONEX and PLEGRIDY.
Analysis of change in reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
2019 |  |  |  |  |  |  |
Beginning balance | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year | 666.2 |  |  | 3,011.5 |  |  | 20.9 |  |  | 3,698.6 |
Adjustments relating to prior years | 0.3 |  |  | (54.1 | ) |  | 5.5 |  |  | (48.3 | )
Payments/returns relating to sales in current year | (535.5 | ) |  | (2,242.9 | ) |  | (0.2 | ) |  | (2,778.6 | )
Payments/returns relating to sales in prior years | (127.7 | ) |  | (576.0 | ) |  | (20.4 | ) |  | (724.1 | )
Ending balance | $ | 131.1 |  |  | $ | 1,027.3 |  |  | $ | 40.5 |  |  | $ | 1,198.9 |
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
2018 |  |  |  |  |  |  |
Beginning balance | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Current provisions relating to sales in current year | 679.3 |  |  | 2,686.7 |  |  | 23.1 |  |  | 3,389.1 |
Adjustments relating to prior years | (0.3 | ) |  | (10.0 | ) |  | (1.8 | ) |  | (12.1 | )
Payments/returns relating to sales in current year | (551.7 | ) |  | (1,887.6 | ) |  | (1.1 | ) |  | (2,440.4 | )
Payments/returns relating to sales in prior years | (109.1 | ) |  | (506.3 | ) |  | (31.5 | ) |  | (646.9 | )
Ending balance | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
2017 |  |  |  |  |  |  |
Beginning balance | $ | 71.6 |  |  | $ | 482.7 |  |  | $ | 51.2 |  |  | $ | 605.5 |
Current provisions relating to sales in current year | 583.0 |  |  | 2,307.4 |  |  | 26.9 |  |  | 2,917.3 |
Adjustments relating to prior years | (0.1 | ) |  | 15.0 |  |  | (8.9 | ) |  | 6.0 |
Payments/returns relating to sales in current year | (475.8 | ) |  | (1,756.9 | ) |  | (0.1 | ) |  | (2,232.8 | )
Payments/returns relating to sales in prior years | (69.1 | ) |  | (442.2 | ) |  | (23.1 | ) |  | (534.4 | )
Ending balance | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Total reserves included in consolidated balance sheet | The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
| As of December 31,
(In millions) | 2019 |  | 2018
Reduction of accounts receivable | $ | 197.8 |  |  | $ | 176.6 |
Component of accrued expenses and other | 1,001.1 |  |  | 874.7 |
Total revenue-related reserves | $ | 1,198.9 |  |  | $ | 1,051.3 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ | 1,542.4 |  |  | $ | 1,431.9 |  |  | $ | 1,316.4 |
Other revenues from anti-CD20 therapeutic programs | 748.0 |  |  | 548.3 |  |  | 242.8 |
Total revenues from anti-CD20 therapeutic programs | $ | 2,290.4 |  |  | $ | 1,980.2 |  |  | $ | 1,559.2 |
Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ | 1,542.4 |  |  | $ | 1,431.9 |  |  | $ | 1,316.4 |
Other revenues from anti-CD20 therapeutic programs | 748.0 |  |  | 548.3 |  |  | 242.8 |
Total revenues from anti-CD20 therapeutic programs | $ | 2,290.4 |  |  | $ | 1,980.2 |  |  | $ | 1,559.2 |
Other revenues | Other revenues are summarized as follows:
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Revenues from collaborative and other relationships: |  |  |  |  |
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc. | $ | — |  |  | $ | (8.6 | ) |  | $ | (16.9 | )
Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis | 106.2 |  |  | 96.4 |  |  | 42.7 |
Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX | — |  |  | — |  |  | 10.7 |
Other royalty and corporate revenues: |  |  |  |  |
Royalty | 17.0 |  |  | 38.7 |  |  | 69.8 |
Other corporate | 584.5 |  |  | 459.4 |  |  | 253.7 |
Total other revenues | $ | 707.7 |  |  | $ | 585.9 |  |  | $ | 360.0 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration